GlassScriptPhysician profile
Garland James
NPI 1255968434
$85,579.38
in general payments reported to CMS, 2019-2025
34 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,706 · 2022: $8,459 · 2023: $12K · 2024: $28K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $25K · Food and Beverage: $14K · Travel and Lodging: $6,053 · Education: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,166.00 |
| Consulting Fee | $25,059.24 |
| Food and Beverage | $13,567.27 |
| Travel and Lodging | $6,053.20 |
| Education | $567.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $46,851.48 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $9,427.21 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $5,473.92 | 2021-2025 | Bimzelx |
| Eli Lilly and Company | $5,422.25 | 2023-2025 | Ebglyss |
| Abbvie INC. | $3,533.49 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,288.09 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $2,156.22 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $1,357.24 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $1,340.28 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $1,259.28 | 2021-2025 | |
| Incyte Corporation | $1,169.46 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,017.01 | 2021-2025 | Ilumya |
| Pfizer INC. | $803.27 | 2021-2025 | |
| Allergan, INC. | $509.78 | 2021-2022 | |
| Almirall LLC | $375.66 | 2021-2023 | Klisyri |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $348.50 | 2023-2025 | Zoryve |
| Amgen INC. | $346.64 | 2021-2024 | Otezla |
| Novartis Pharmaceuticals Corporation | $304.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.08 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $220.10 | 2022-2025 | Nemluvio, Epsolay, Aklief |
| Janssen Scientific Affairs, LLC | $198.02 | 2022-2025 | Tremfya |
| Vyne Pharmaceuticals INC. | $186.24 | 2021 | |
| Organon LLC | $139.85 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $114.40 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Journey Medical Corporation | $105.77 | 2022-2025 | |
| Botanix Sb INC | $87.58 | 2025 | Sofdra |
| Mallinckrodt Hospital Products INC. | $85.12 | 2024 | Acthar |
| Mayne Pharma Commercial LLC | $51.82 | 2021-2023 | |
| Biofrontera INC. | $48.87 | 2021-2022 | |
| Strata Skin Sciences, INC. | $39.76 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $35.94 | 2021 | |
| Celgene Corporation | $26.00 | 2022 | |
| Dermira, INC. | $12.28 | 2021 | |
| Kerecis Limited | $10.00 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garland James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.